Lenvatol 4mg Capsule contains Lenvatinib, a potent multi-kinase inhibitor used primarily in the treatment of various malignancies. Lenvatinib exerts its therapeutic effect by selectively inhibiting receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. This mechanism disrupts tumor blood supply and growth, making Lenvatol effective in managing differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma, among other cancers. The 4mg dosage is typically prescribed based on patient-specific factors such as tumor type, stage, and tolerability. Lenvatol should be administered orally once daily, with or without food, as directed by a healthcare professional. Patients receiving Lenvatinib require regular monitoring for adverse effects, including hypertension, proteinuria, fatigue, diarrhea, and potential hepatic or renal impairment. Dose adjustments may be necessary in response to toxicity or adverse reactions. Lenvatol is contraindicated in patients with known hypersensitivity to Lenvatinib or its components. Due to its teratogenic potential, effective contraception is advised during treatment and for a specified period afterward. This medication should be used under strict medical supervision to optimize therapeutic outcomes while minimizing risks.